Melatonin prevents deterioration of erectile function in streptozotocin-induced diabetic rats via sirtuin-1 expression.
Study Goal
The researchers aimed to evaluate the protective effects of melatonin on erectile function and sirtuin-1 protein expression in type 1 diabetic rat models.
Results Summary
The study investigated melatonin's role in improving erectile function in diabetic rats, but the abstract does not provide specific results regarding its efficacy or outcomes.
Population
Male Sprague Dawley rats with induced type 1 diabetes.
Effective Dosage
10 mg/kg (frequency not specified).
Duration
Not specified in the abstract.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin therapy | no change | sirtuin-1 expression | erectile dysfunction (ED) | - | has not yet been investigated | #1 |
melatonin | increase | erectile function | type 1 diabetic rat models | - | protective effects | #2 |
streptozotocin | increase | diabetes | male Sprague Dawley rats | 60 mg/kg | to induce diabetes | #3 |
insulin | neutral | - | male Sprague Dawley rats | 6 U/kg/day | - | #4 |
melatonin | neutral | - | male Sprague Dawley rats | 10 mg kg | - | #5 |
A review of the literature indicated that sirtuin-1 expression, a regulator of nitric oxide bioavailability in erectile dysfunction (ED) after melatonin therapy, has not yet been investigated. The objective of this study was to evaluate the protective effects of melatonin for erectile function with sirtuin-1 protein expression in type 1 diabetic rat models. Fifty male Sprague Dawley rats were placed into five groups. Except for those in the control group (C), each animal received a single dose (60 mg/kg) of streptozotocin to induce diabetes. The animals were placed into the diabetes (D) group, insulin (I) group (6 U/kg/day), melatonin (Mel) group (10 mg kg